Patent Expiry

Patent/Exclusivity Expiry: ORLADEYO

November 1, 2039

Company: BIOCRYST PHARMACEUTICALS INC (BCRX)
Drug: ORLADEYO

Other upcoming events for BCRX

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar